Objective: We prospectively screened a large European cohort of patients presenting with hyperCKemia and/or limb-girdle muscular weakness (LGMW) for acid a-glucosidase (GAA) deficiency by dried blood spot (DBS) investigation.
Sampling and fluorometry. A blood sample was collected from a peripheral vein in an EDTA-coated tube, and blood was immediately afterward spotted onto a filter paper (Whatman 903 Specimen Collection Paper). All samples were anonymized and analyzed at the Metabolic Laboratory, Institute of Clinical Chemistry, Hamburg University Medical Centre, Germany. A fluorometric assay was used for analysis. 5 Statistics. For descriptive statistical analyses, the statistics program SPSS for Windows version 23.0 (IBM Corp., Armonk, NY) was used.
Gene sequencing. Sanger sequencing of the coding and exon flanking region of the GAA gene was performed if the DBS activity of GAA was below 0.9 nmol/punch 3 21 hours in 2 independently taken DBS samples.
Standard protocol approvals, registrations, and patient consents. Oral and written informed consent was obtained from all participants before blood sampling. The study was conducted in accordance with the Declaration of Helsinki. The study was approved by the ethics committee of the Ludwig Maximilian University of Munich, Germany (no. 201-09).
RESULTS
The cohort included 3,076 patients aged between 18 and 89 years with a median of 48 years of participation (58.2% women). The demographic and clinical presentation of the studied cohort is summarized in table 1. GAA activity results were within the normal range for 2,844 patients (92.2%). The average value of CK levels in all patients was 563 (SD 371) IU/L (normal range, 15,000 IU/L). DBS activity of GAA was below the cutoff of 0.9 nmol/punch 3 21 hours in 232 patients with a median age of 40.7 years.
On average, the DBS GAA activity with the specific inhibitor acrabose was 1.73 nmol/punch 3 21 hours (median 1.22 nmol/punch 3 21 hours) in nonaffected individuals. In contrast, all 74 patients with finally confirmed Pompe disease showed an average GAA activity with inhibitor of 0.18 nmol/punch 3 21 hours (median 0.12 nmol/punch 3 21 hours). Forty-two women (56%) and 32 men were finally diagnosed by mutational analysis as having late-onset Pompe disease. Sequencing of the GAA gene revealed 2 heterozygous known pathogenic mutations, including the common GAA gene splice-site mutation c.-32-13T.G on one allele in 70 patients, confirming the diagnosis. One hundred fifty-eight possible carriers of Pompe disease were also identified by borderline GAA enzyme activity; however, a second DBS test had normal GAA enzyme activities in 123 patients. . In 95 patients, the borderline GAA enzyme activity and diagnosis remained unsolved. In 24 of these 95 patients, a second DBS test could not be performed. Eleven patients were found to be heterozygous for the common splice-site GAA gene mutation c.-32-13T.G without detection of a second GAA gene mutation.
DISCUSSION This is the largest prospective cohort screening for late-onset Pompe disease in a population of unclassified muscle diseases so far. The screening efficacy of DBS has been described in newborn screening and other smaller focused studies in Pompe disease (table 2) . [6] [7] [8] [9] [10] [11] [12] All 74 of our newly diagnosed patients with Pompe disease revealed the clinical key elements of late-onset Pompe disease (table 1) . In our study, the main finding is the prevalence of adult Pompe disease of 2.4% in patients with unclassified LGMW and/or hyperCKemia. This finding is in accordance with smaller published studies, with a combined prevalence of 2.5%. [6] [7] [8] [9] [10] [11] [12] Although using similar fluorometric assays, all 8 DBS screening studies show a slight difference in the prevalence. These differences may reflect country-specific differences in the frequency of a rare disease. In the Black American, Dutch, and Taiwanese populations, there is known to be a higher prevalence of Pompe disease compared to other countries worldwide.
1,4 Deficient DBS GAA activity cannot always be confirmed on analysis of a second sample. Known reasons include blood draw after transfusion, incorrect DBS spotting and sampling, and environmental circumstances such as high temperature during transport. Even in this study of experienced centers, errors in spotting the blood or environmental conditions cannot be Table 1 Demographic and clinical presentation of the study cohort completely excluded. However, the internal control of the DBS assay by measurement of neutral maltase activity was performed in all assays and was acceptable in the first sample for our patients. There is still a chance of a false-positive result; therefore, we recommend that DBS GAA deficiency be confirmed using a second tissue, e.g., fibroblasts, muscle, or the gold standard of GAA Sanger gene sequencing. Classically, muscle biopsy in late-onset Pompe disease shows autophagic vacuolar myopathic changes, glycogen accumulation, and acid phosphatase-positive inclusions. The latter may be seen without obvious glycogen accumulation. However, it is well recognized by neuromuscular specialists that glycogen accumulation and acid phosphatase inclusions may be absent, and if so, that should not preclude DBS analysis. Arguably, DBS could be performed before biopsy whenever there is a clinical suspicion of Pompe disease. Given the relative rarity of late-onset Pompe disease, the relatively nonspecific clinical features of proximal weakness and elevated CK, and the frequent absence of diagnostic muscle biopsy findings, even experienced neuromuscular clinicians may not consider the diagnosis.
On the basis of our findings, we recommend that a DBS test be undertaken early in the diagnostic workup of patients with unclassified LGMW or persistent hyperCKemia to exclude late-onset Pompe disease. Key clinical elements that should alert clinicians to perform a DBS screening for late-onset Pompe disease are (1) axial, pelvic, and respiratory muscle involvement, and (2) persistent CK elevation.
Finally, there is growing evidence to suggest that early treatment of late-onset Pompe disease with enzyme replacement therapy, before there is extensive, possibly irreversible muscle damage, is more efficacious than later treatment, emphasizing the importance of early diagnosis. 
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